(1)
SpyBiotech has raised $32.5M from leading investors to advance development of its novel plug and display vaccine platform technology
Braavos Investment Advisers led the round, joined by new investor Oxford Investment Consultants; founding investors Oxford Sciences Innovation and GV also participated
Lutz B. Giebel joins as Chairman, strengthening governance as company expands clinical development and builds operational resource
OXFORD, United Kingdom, Feb. 10, 2021 (GLOBE NEWSWIRE) SpyBiotech, a British biotechnology company with a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, today announces it has raised $32.5 million in Series A equity financing and appointed Lutz B. Giebel as Chairman.
Investegate announcements from SpyBiotech, SpyBiotech raises $32.5M in Series A funding and appoints Lutz B. Giebel as Chairman to support its novel vaccine platform through accelerated clinical development
Defra unveils £10m fund for nature-based climate solutions
The Government has unveiled a new £10m fund to support nature-based projects that combat the climate crisis, in the same week that Oxford University launched a new venture studio designed to uncover similar solutions.
The fund will support key legislative frameworks, including the 25 Year Environment Plan
Delivered by the Environment Agency on behalf of Defra, the new £10m fund offers grants of up to £100,000 to projects that will create and restore natural habitats while assisting with key government frameworks.
The Natural Environment Investment Readiness Fund is open for applications until 28 March and will support the creation of new coastal wetlands, the restoration of river catchments that reduce flood risk and the creation of new woodlands and peatlands that support carbon sequestration.
The fund has been seeded with a $25 million special purpose investment vehicle.
The world’s first venture capital fund to use conservation technologies from Oxford University was announced Tuesday by venture capital firm Global Accelerated Ventures (GAV) and Oxford University Innovation (OUI), the research commercialization arm of the school.
The Oxford GAV Conservation Venture Studio (OXGAV) has funding from a $25 million special purpose investment vehicle (SPV). The founders say the SPV structure will help OXGAV support and bring prototypes to market much more quickly than traditional venture capital structures. It does not charge a 2% management fee, though it keeps the 20% incentive fees.
World-first COVID-19 alternating dose vaccine study launches in UK — Agenparl agenparl.eu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from agenparl.eu Daily Mail and Mail on Sunday newspapers.